Mode
Text Size
Log in / Sign up
N/A Completed N=131 Randomized Treatment

Comparative Outcomes Management With Electronic Data Technology (COMET) Study

Sleep Apnea, Obstructive
Source: ClinicalTrials.gov NCT01461473 ↗
Enrolled (actual)
131
Serious AEs
4.6%
Results posted
May 2017
Primary outcomePrimary: Nocturnal Mean Arterial Blood Pressure (NMAP) at 2 Months — 82.1; 84.3 mmHg — p=0.2067

Summary

STAGE I of the COMET study was to develop an Electronic Network Informatics Infrastructure that prospectively enabled access to and the sharing of clinical and research data. STAGE II: This was a Comparative Effectiveness Trial (CET) evaluating positive airway pressure (PAP) vs. oral appliance (OA) therapy in improving hypertension and abnormalities in cardiovascular function in overweight/obese patients with obstructive sleep apnea (OSA). Data collected during the STAGE II study was incorporated in Part 3 of the STAGE I study. STAGE III of the COMET study was completion of data analysis and preparation of the electronic network informatics infrastructure for use beyond the four Clinical Centers to interested CTSA institutions. We also explored expanding ontologies, and the use of federated database methodology.

Outcome Measures

OutcomeResultp-value
PRIMARY
Nocturnal Mean Arterial Blood Pressure (NMAP) at 2 Months
82.1; 84.3 0.2067
SECONDARY
Nocturnal Mean Arterial Blood Pressure (NMAP) at 6 Months
83.1; 84.7 0.3902
SECONDARY
Ratio of Nocturnal Mean Arterial Pressure (NMAP) to Daytime Mean Arterial Pressure at 2 Months
86.8; 87.0 0.9319
SECONDARY
Ratio of NMAP to Daytime Mean Arterial Pressure at 6 Months
86.6; 87.9 0.3895
SECONDARY
Mean Absolute Flow-Mediated Vasodilatation of the Brachial Artery by Vascular Ultrasound
0.009; 0.012 0.3449
SECONDARY
Mean Relative Flow-Mediated Vasodilatation of the Brachial Artery by Vascular Ultrasound
2.63; 3.51 0.1531

Eligibility Criteria

Inclusion Criteria

  • Age > 18 years.
  • BMI > = 25.0 kg/m^2.
  • A diagnosis of obstructive sleep apnea based upon medical history and apnea- hypopnea index > = 10.0 or oxygen desaturation index (ODI; ≥4%) ≥ 10.0 on Diagnostic Polysomnogram.
  • Report a history of hypertension (or need for treatment for hypertension) which is currently untreated OR taking medication for the treatment of hypertension.
  • Stable medication regimen for 2 months prior to the Baseline Testing Visit. As-needed medications such as those used for allergy, cold, or minor pain symptoms may be used at the discretion of the Clinical Center physician.

Exclusion Criteria

  • Cardiovascular disease which, in the judgment of the investigator, if observed during standard clinical practice would lead the treating physician to make every effort to treat the patient's sleep apnea with positive airway pressure, rather than alternative treatments.
  • Clinically significant acute or chronic disease that is not well controlled or could affect ability to complete or comply with study procedures, in the opinion of the Clinical Center physician.
  • Respiratory disease requiring supplemental oxygen or medication. Individuals with asthma may be included at the discretion of the Clinical Center physician if disease is well controlled and medications are stable for 2 months.
  • History of (within 12 months prior to enrollment), or current diagnosis of, Axis I or Axis II psychiatric disorder (other than obstructive sleep apnea) that in the opinion of the Clinical Center physician would affect ability to complete or comply with study procedures (e.g., schizophrenia and other psychotic disorders).
  • History of (within 3 months prior to enrollment), or current diagnosis of narcolepsy, idiopathic hypersomnia, restless legs syndrome, rapid eye movement (REM) behavior disorder, persistent situational insomnia, or sleep-related breathing disorders other than obstructive sleep apnea.
  • Periodic limb movement arousal index > 10.0 on the Diagnostic Polysomnogram.
  • Significant daytime sleepiness at study entry as indicated by:
  • an Epworth Sleepiness Scale total score > 16, or a score of 3 (high chance) on the question about risk of dozing "In a car, while stopped for a few minutes in traffic" or
  • a report of falling asleep at the wheel, a motor vehicle accident, or near-miss accident due to sleepiness in the past 24 months, which in the judgment of the study physician was not attributable to acute sleep loss.
  • Oxygen saturation 10% of sleep time during the Diagnostic Polysomnogram, or intervention with positive airway pressure or oxygen for safety purposes during the Diagnostic Polysomnogram.
  • Any prior treatment for obstructive sleep apnea with positive airway pressure or oral appliance, or surgical treatment for obstructive sleep apnea in the past year.
  • Contraindication for treatment with either positive airway pressure or oral appliance, in the opinion of the Clinical Center physician or dentist, including significant nasal obstruction, insufficient or loose teeth, dentures, advanced periodontal disease, or significant temporomandibular joint pain.
  • Pregnancy.
  • Difficulty understanding or speaking English, or inability to read and understand informed consent and study procedures.
  • Significant vision, hearing, or motor problems that, in the opinion of the Clinical Center physician, would affect ability to complete study procedures.
  • A work schedule that does not allow for nighttime sleep on the 3 nights before each study visit.
  • Current or planned participation in another research study.
  • Metal objects, devices, or implants that are in or on the body (Stanford Clinical Center only).
  • Creatinine clearance 1.6 (Stanford Clinical Center only).
  • Upper arm circumference > 20 inches
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01461473). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search